Gavaldà J et al. |
Immunogenicity of pandemic influenza A H1N1/2009 adjuvanted vaccine in pediatric solid organ transplant recipients. |
2013 |
Pediatr Transplant |
pmid:23692602
|
Vera-Lastra O et al. |
Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. |
2013 |
Expert Rev Clin Immunol |
pmid:23557271
|
Singh M et al. |
MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. |
2012 |
Hum Vaccin Immunother |
pmid:22832252
|
Vesikari T et al. |
Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. |
2012 |
Hum Vaccin Immunother |
pmid:22906943
|
Della Cioppa G et al. |
Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults. |
2012 |
Hum Vaccin Immunother |
pmid:22426371
|
Ikematsu H et al. |
Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. |
2012 |
Hum Vaccin Immunother |
pmid:22854661
|
Faenzi E et al. |
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. |
2012 |
Vaccine |
pmid:22521851
|
Hatz C et al. |
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. |
2012 |
Vaccine |
pmid:22626675
|
Hwang SM et al. |
Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers. |
2012 |
Jpn. J. Infect. Dis. |
pmid:22627298
|
Siegrist CA et al. |
Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. |
2012 |
Antivir. Ther. (Lond.) |
pmid:22544169
|
Yang M et al. |
MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. |
2012 |
Int. Immunopharmacol. |
pmid:22595192
|
Cabrera-Vique C et al. |
Bioactive compounds and nutritional significance of virgin argan oil--an edible oil with potential as a functional food. |
2012 |
Nutr. Rev. |
pmid:22537213
|
Stella B et al. |
Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits. |
2012 |
Eur J Pharm Biopharm |
pmid:22008147
|
Nakazawa A et al. |
Optimization of culture conditions of the thraustochytrid Aurantiochytrium sp. strain 18W-13a for squalene production. |
2012 |
Bioresour. Technol. |
pmid:22023965
|
Niehaus TD et al. |
Functional identification of triterpene methyltransferases from Botryococcus braunii race B. |
2012 |
J. Biol. Chem. |
pmid:22241476
|
Iorio AM et al. |
Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. |
2012 |
Vaccine |
pmid:22245606
|
Ambrose CS and Belshe RB |
Influenza vaccine in young children. |
2012 |
N. Engl. J. Med. |
pmid:22276839
|
Heikkinen T and Heinonen S |
Influenza vaccine in young children. |
2012 |
N. Engl. J. Med. |
pmid:22276840
|
Gasparini R et al. |
Aflunov(®): a prepandemic influenza vaccine. |
2012 |
Expert Rev Vaccines |
pmid:22309663
|
Spanova M et al. |
Influence of squalene on lipid particle/droplet and membrane organization in the yeast Saccharomyces cerevisiae. |
2012 |
Biochim. Biophys. Acta |
pmid:22342273
|
RamÃrez-Torres A et al. |
Proteomics and gene expression analyses of squalene-supplemented mice identify microsomal thioredoxin domain-containing protein 5 changes associated with hepatic steatosis. |
2012 |
J Proteomics |
pmid:22796066
|
Surls J et al. |
Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response. |
2012 |
PLoS ONE |
pmid:22723880
|
Girod A et al. |
Composition of fingermark residue: a qualitative and quantitative review. |
2012 |
Forensic Sci. Int. |
pmid:22727572
|
Sarpietro MG et al. |
Squalenoyl prodrug of paclitaxel: synthesis and evaluation of its incorporation in phospholipid bilayers. |
2012 |
Int J Pharm |
pmid:22728161
|
Wu S et al. |
Engineering triterpene metabolism in tobacco. |
2012 |
Planta |
pmid:22729821
|
Langley JM et al. |
Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. |
2012 |
Pediatr. Infect. Dis. J. |
pmid:22801094
|
Block SL et al. |
Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. |
2012 |
Pediatr. Infect. Dis. J. |
pmid:22481427
|
Sémiramoth N et al. |
Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections. |
2012 |
ACS Nano |
pmid:22482704
|
Langley JM et al. |
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. |
2012 |
Vaccine |
pmid:22469860
|
Fukase H et al. |
Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. |
2012 |
Vaccine |
pmid:22472791
|
Suthiwong J et al. |
A new phenolic compound from the stem of Hymenocardia wallichii. |
2012 |
J Asian Nat Prod Res |
pmid:22423644
|
Zhang XH et al. |
Chemical composition of volatile oils from the pericarps of Indian sandalwood (Santalum album) by different extraction methods. |
2012 |
Nat Prod Commun |
pmid:22428257
|
Guzmán Herrador BR et al. |
Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway. |
2012 |
BMC Infect. Dis. |
pmid:22429643
|
Hatz C et al. |
A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. |
2012 |
Vaccine |
pmid:22446638
|
Lai RP et al. |
Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. |
2012 |
PLoS ONE |
pmid:22509385
|
Marinaro M et al. |
A caprine herpesvirus 1 vaccine adjuvanted with MF59â„¢ protects against vaginal infection and interferes with the establishment of latency in goats. |
2012 |
PLoS ONE |
pmid:22511971
|
Cosco D et al. |
Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. |
2012 |
Int J Nanomedicine |
pmid:22679366
|
Fox CB et al. |
Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. |
2012 |
AAPS PharmSciTech |
pmid:22415641
|
Nassim C et al. |
Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. |
2012 |
Pediatr. Infect. Dis. J. |
pmid:22418661
|
Fox CB et al. |
Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. |
2012 |
Clin. Vaccine Immunol. |
pmid:22896687
|
Reynales H et al. |
A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. |
2012 |
Vaccine |
pmid:22902681
|
Desmaële D et al. |
Squalenoylation: a generic platform for nanoparticular drug delivery. |
2012 |
J Control Release |
pmid:21840355
|
Naziri E et al. |
Recovery of squalene from wine lees using ultrasound assisted extraction-a feasibility study. |
2012 |
J. Agric. Food Chem. |
pmid:22888984
|
Czajka H et al. |
A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. |
2012 |
J Prev Med Hyg |
pmid:23362618
|
Takami T et al. |
A genetic and pharmacological analysis of isoprenoid pathway by LC-MS/MS in fission yeast. |
2012 |
PLoS ONE |
pmid:23145048
|
Langley JM et al. |
A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. |
2012 |
BMC Infect. Dis. |
pmid:23110320
|
Bihari I et al. |
Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects. |
2012 |
Clin. Vaccine Immunol. |
pmid:23081815
|
Tetsutani K and Ishii KJ |
Adjuvants in influenza vaccines. |
2012 |
Vaccine |
pmid:23084848
|
Liu YT et al. |
Protein engineering of Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase into parkeol synthase. |
2012 |
Org. Lett. |
pmid:23043506
|
Ta MT et al. |
Accumulation of squalene is associated with the clustering of lipid droplets. |
2012 |
FEBS J. |
pmid:23013491
|